JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...
Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...
NasdaqGS:NBIX Earnings and Revenue History February 21st 2025 Examining Cashflow Against Neurocrine Biosciences' Earnings. As finance nerds would already know, the accrual ratio f ...
NasdaqGS:NBIX Earnings and Revenue History February 21st 2025 Examining Cashflow Against Neurocrine Biosciences' Earnings. As finance nerds would already know, the accrual ratio f ...
Biosciences announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...
StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating ...
Tumbling to a price of $128.32 during today's morning trading session, shares of Neurocrine Biosciences are now -24.61% below their average target price of $170.22. Does this mean the stock will ...
Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...